| [1] |
|
| [2] |
|
| [3] |
Yi SW, Lee JH, Hong JM, et al. Incidence, disability, and mortality in patients with Guillain-Barré syndrome in Korea: a nationwide population-based study[J]. J Clin Neurol, 2022, 18(1): 48-58. DOI: 10.3988/jcn.2022.18.1.48.
|
| [4] |
Zheng P, Tian DC, Xiu Y, et al. Incidence of Guillain-Barré syndrome (GBS) in China: a national population-based study[J]. Lancet Reg Health West Pac, 2022, 18: 100302. DOI: 10.1016/j.lanwpc.2021.100302.
|
| [5] |
Yuki N, Hartung HP. Guillain-Barré syndrome[J]. N Engl J Med, 2012, 366(24): 2294-2304. DOI: 10.1056/NEJMra1114525.
|
| [6] |
Wu Q, Liu N, Pan C, et al. Guillain-Barré syndrome and cerebral hemorrhage: two cases and literature review[J]. Eur Neurol, 2016, 76(3-4): 182-186. DOI: 10.1159/000450603.
|
| [7] |
Hu J, Luo X, Wang Y, et al. Fulminant Guillain-Barré syndrome and spontaneous intraventricular hemorrhage: a case report and literature review[J]. Front Neurosci, 2020, 14: 633. DOI: 10.3389/fnins.2020.00633.
|
| [8] |
Li X, Xiao J, Ding Y, et al. Clinical and electrophysiological features of post-traumatic Guillain-Barré syndrome[J]. BMC Neurol, 2017, 17(1): 142. DOI: 10.1186/s12883-017-0919-x.
|
| [9] |
Jin J, Hu F, Qin X, et al. Very Early Neurophysiological Study in Guillain-Barre Syndrome[J]. Eur Neurol, 2018, 80(1-2):100-105. DOI: 10.1159/000494261.
|
| [10] |
Rasera A, Romito S, Segatti A, et al. Very early and early neurophysiological abnormalities in Guillain-Barré syndrome: A 4-year retrospective study[J]. Eur J Neurol, 2021, 28(11): 3768-3773. DOI: 10.1111/ene.15011.
|
| [11] |
Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps[J]. Nat Rev Neurol, 2019, 15(11): 671-683. DOI: 10.1038/s41582-019-0250-9.
|
| [12] |
Goodfellow JA, Willison HJ. Guillain-Barré syndrome: a century of progress[J]. Nat Rev Neurol, 2016, 12(12): 723-731. DOI: 10.1038/nrneurol.2016.172.
|
| [13] |
Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial[J]. Lancet Neurol, 2018, 17(6): 519-529. DOI: 10.1016/S1474-4422(18)30114-5.
|
| [14] |
Yoon MS, Pitarokoili K, Sturm D, et al. Treatment of an acute motor and sensory axonal neuropathy with propionate in a 33-year-old male[J]. Ther Adv Neurol Disord, 2018, 11: 1756286418809580. DOI: 10.1177/1756286418809580.
|
| [15] |
Wen P, Wang L, Liu H, et al. Risk factors for the severity of Guillain-Barré syndrome and predictors of short-term prognosis of severe Guillain-Barré syndrome[J]. Sci Rep, 2021, 11(1): 11578. DOI: 10.1038/s41598-021-91132-3.
|
| [16] |
Wei JW, Huang Y, Wang JG, et al. Current management of intracerebral haemorrhage in China: a national, multi-centre, hospital register study[J]. BMC Neurol, 2011, 11: 16. DOI: 10.1186/1471-2377-11-16.
|
| [17] |
Shi M, Zhu J, Deng H. Clinical characteristics of intravenous injection of monosialotetrahexosyl ganglioside sodium-related Guillain-Barre syndrome[J]. Front Neurol, 2019, 10: 225. DOI: 10.3389/fneur.2019.00225.
|
| [18] |
|
| [19] |
Paz P, Pan J, Ball S. Teaching NeuroImages: Extrapontine osmotic demyelination in hypernatremia[J]. Neurology, 2020, 94(16): e1780-e1781. DOI: 10.1212/WNL.0000000000009299.
|
| [20] |
Han MJ, Kim DH, Kim YH, et al. A case of osmotic demyelination presenting with severe hypernatremia[J]. Electrolyte Blood Press, 2015, 13(1): 30-36. DOI: 10.5049/EBP.2015.13.1.30.
|
| [21] |
Auger N, Quach C, Healy-Profitós J, et al. Early predictors of Guillain-Barré syndrome in the life course of women[J]. Int J Epidemiol, 2018, 47(1): 280-288. DOI: 10.1093/ije/dyx181.
|
| [22] |
Bragazzi NL, Kolahi AA, Nejadghaderi SA, et al. Global, regional, and national burden of Guillain-Barré syndrome and its underlying causes from 1990 to 2019[J]. J Neuroinflammation, 2021, 18(1): 264. DOI: 10.1186/s12974-021-02319-4.
|
| [23] |
|